INTRODUCTION

Symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM) are treated to reduce symptoms, improve functional capacity and provide better quality of life. Therefore, the extent of the outflow tract gradient and diastolic filling must be improved. Medical therapy, with the administration of negative inotropic drugs such as beta-blockers, verapamil or disopyramide, is always the first line of treatment. A large number of patients with marked outflow tract obstruction have severe symptoms which are unresponsive to medical therapy. In this group, surgical myectomy/myotomy has been the mainstay for decades, providing long-term symptomatic relief in a substantial proportion of patients. The high early postoperative mortality could be reduced to <1%-2% in highly experienced centers. DDD-pacemaker implantation has not proved to be as efficacious in randomized trials, with most of the reported reduction of symptoms being due to a substantial placebo effect.

Percutaneous transluminal septal myocardial ablation (PTSMA) through alcohol-induced occlusion of a septal branch aims to directly reduce the hypertrophied interventricular septum with subsequent expansion of the left ventricular outflow tract and reduction of the left ventricular outflow tract gradient. This is achieved through a circumscribed infarction of the area supplied by the occluded septal branch. In this report we give an update on this novel treatment.

TECHNICAL ASPECTS

After initial studies had shown that temporary balloon occlusion of the first large septal branch resulted in a substantial reduction in resting outflow gradient in a minority of patients, Sigwart was the first to report successful non-surgical myocardial reduction after occlusion of the septal branch with 96% alcohol.

The original technique of PTSMA has undergone several modifications to date, with the aim of improving the identification of the target septal perforator branch, in order to achieve optimal hemodynamic results with fewer complications. Nearly all operators agree that a temporary pacemaker should be placed in the right ventricle because of the risk of trifascicular block during PTSMA. Currently, echocardiography-guided ablation is performed by most active PTSMA groups. We will briefly discuss the advantages of this technique. Echocardiographic monitoring of the procedure was introduced in order to identify the target septal branch and to exclude unintentional alcohol injection to the wrong area, e.g., the papillary muscle or left ventricular free wall (Figure 1). The authors have chosen Levovist® instead of other echo-contrast media, due to its superior visibility during the procedure. Finally, it must be emphasized that hemodynamic and rhythm monitoring in the coronary care unit is required for at least 24 to 48 hours.
INDICATIONS AND CONTRAINDICATIONS

The clinical indications for PTSMA are symptomatic patients ≥NYHA III/CCS III despite optimal drug therapy or with severe side effects from medication. The patients should have high outflow tract gradients (≥50 mm Hg at rest or ≥100 mm Hg under stress). In individual patients with less severe symptoms, active treatment can be considered if they have high gradients and additional findings, such as recurrent exercise-induced syncope, abnormal blood pressure response on exercise, paroxysmal atrial fibrillation or an objective reduction in exercise capacity. These considerations are supported by current data that have shown a correlation between hypertrophic cardiomyopathy-related death as well as progressive heart failure and a resting gradient of more than 30 mm Hg.23,24 The morphological indications for echocardiography-guided septal ablation are subaortic as well as mid-cavitary obstruction, previous hemodynamically unsuccessful surgical myectomy, or DDD-pacemaker implantation. Patients with concomitant cardiac diseases indicating surgery, e.g., extensive coronary artery disease, valvular disease, and anatomical changes in the mitral valve or the papillary muscles that cause an outflow tract gradient or mitral regurgitation, should not be treated with PTSMA. It must be noted, however, that in individual patients with single vessel disease amenable to dilatation and stenting, combined percutaneous treatment (percutaneous transluminal coronary angioplasty and PTSMA) has been performed.25

Finally, alcohol should not be injected when myocardial contrast echocardiography fails to identify a target septal branch, or reveals opacification of any cardiac structure other than the target septal area, or when balloon positioning bears the risk of alcohol reflux during injection.

RESULTS

All operators report an acute reduction in left ventricular outflow tract gradient in about 90% of the patients treated.17,18,20,21,26-34 Younger patients had smaller reductions in the gradient than older patients,35 probably because of greater septal thickness and additional structural deformities such as abnormal papillary muscles. Nevertheless, about 50% of the young patients with inadequate acute results show improved gradient reduction at follow-up, due to post-infarction remodeling and shrinkage of the ablated area of the septum. Patients in functional class IV showed acute results similar to those in less symptomatic patients.36 In patients with a PTSMA scar that appears too small, the outcome of the remodeling process, which can take up to 12 months, should be awaited. Pre-interventional non-invasive estimation of the underlying histological substrate (fibrosis or muscle) and elongation of the mitral leaftlet will probably be helpful in the future to exclude patients from PTSMA, in order to optimize hemodynamic success. Several studies have reported that echo-guidance with myocardial contrast echocardiography (MCE) had a crucial impact on the selection of the ablated area in about a quarter of the patients.17 Echo-contrast helped to identify an atypical origin in the septal branch as the target vessel, or to avoid injecting alcohol into the wrong site by changing the vessel when echo-contrast opacification had identified the wrong septal areas or other cardiac structures, such as papillary muscles or ventricular free walls. Our findings were confirmed in an autopsy study by Singh et al.37 Furthermore,
Echocardiographic monitoring also permitted the interventional treatment of combined subaortic and mid-ventricular obstruction, as well as a pronounced mid-ventricular obstruction following the reduction of its afterload after successful subaortic myectomy.38

In-hospital death is the most feared complication observed to date, with a rate of up to 4%.31 In our own experience with PTSMA in >600 patients, hospital mortality has been less than 1.0%, which is similar to the results from highly experienced surgical myectomy centers (Table 1). These deaths occurred only in older patients and during the post-interventional period, which underlines the importance of careful hospital monitoring. Reports of delayed occurrence of complete heart block up to 10 days after the intervention deserve careful attention, as this event emphasizes the need for close monitoring for arrhythmia during several days after the intervention.39

After the introduction of MCE the number of permanent pacemaker implantations for permanent trifascicular block was reduced to less than 5%, a figure approaching the range of postoperative implantations.10 Furthermore, the development of complete heart block after septal ablation can be predicted using a score introduced by Faber et al.40 In addition to trifascicular blocks, all groups reported the occurrence of bundle-branch block in about 50% of the patients, predominantly involving the right bundle branch, in contrast to many patients after surgical myectomy who develop left bundle branch block.

In contrast to myocardial infarction due to coronary artery disease, the incidence of significant ventricular dysrhythmia during and after ablation is very low. Another worrisome complication is iatrogenic reflux of alcohol into the left anterior descending coronary artery with transitory vessel occlusion and anterolateral ischemia.26,34 This can be avoided by technical improvements such as the use of a slightly oversized balloon and at least 10 minutes of continuous balloon inflation after the last alcohol injection.

Follow-up studies lasting up to 6 years have shown no increased risk of sudden death or arrhythmic complications.41 On the contrary, an impressive, steady and progressive improvement in symptoms, accompanied by an increase in objective measurements of exercise capacity, is clearly seen.17,26,41-43 Echocardiographic measurements document continued progressive reduction of the left ventricular outflow tract gradient.17,41 After a mean follow-up of 43 months, 90% of the patients showed complete elimination of the outflow tract gradient. This should be interpreted as an expression of post-interventional remodeling that follows induced septal infarction, analogous to the remodeling following acute myocardial infarction. These findings also underscore the aim of our strategy to induce septal necrosis by alcohol ablation: although it should be large enough to be effective, it should also be kept as small as possible.

Remodeling after PTSMA results in reductions in

<table>
<thead>
<tr>
<th>Author</th>
<th>Patients (n)</th>
<th>Success without complication (%)</th>
<th>Death (%)</th>
<th>Pacemaker (%)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seggewiss et al20</td>
<td>25</td>
<td>88</td>
<td>4.0</td>
<td>20</td>
<td>No echo-monitoring</td>
</tr>
<tr>
<td>Faber et al21</td>
<td>91</td>
<td>97%</td>
<td>2.2</td>
<td>11</td>
<td>Improvement of results by echo-monitoring</td>
</tr>
<tr>
<td>Gietzen et al31</td>
<td>50</td>
<td>NR</td>
<td>4.0</td>
<td>NR</td>
<td>12 re-interventions; no echo-monitoring</td>
</tr>
<tr>
<td>Nagueh et al32</td>
<td>29</td>
<td>NR</td>
<td>0</td>
<td>10 (34%)</td>
<td>4 patients with gradients only at dobutamine infusion</td>
</tr>
<tr>
<td>Knight et al26</td>
<td>18</td>
<td>89</td>
<td>0</td>
<td>5*</td>
<td>1 patient alcohol leakage down the LAD</td>
</tr>
<tr>
<td>Kornacewicz-Jach et al29</td>
<td>9</td>
<td>100</td>
<td>0</td>
<td>22</td>
<td>Echo-monitoring</td>
</tr>
<tr>
<td>Kuhn et al27</td>
<td>172</td>
<td>NR</td>
<td>2.3</td>
<td>NR</td>
<td>No echo-monitoring</td>
</tr>
<tr>
<td>Seggewiss17</td>
<td>290</td>
<td>90</td>
<td>1.0</td>
<td>5.5</td>
<td>DDD-pacemaker with echo-monitoring 4.2%</td>
</tr>
<tr>
<td>Boekstegers et al33</td>
<td>50</td>
<td>NR</td>
<td>0</td>
<td>10</td>
<td>No echo-monitoring; 2 septal branches in 6 patients</td>
</tr>
<tr>
<td>Gietzen et al31</td>
<td>129</td>
<td>NR</td>
<td>3.1</td>
<td>26</td>
<td>No echo-monitoring; similar results in patients with and without resting obstruction</td>
</tr>
</tbody>
</table>

Schweinfurt (Seggewiss et al 5/00-4/02) 150 92 0.7 1.3 Echo-monitoring

LV indicates left ventricle; LAD, left anterior descending artery; NR, not reported.
*6 patients with pacemaker implantation before PTSMA.
both ventricular septal thickness and left ventricular posterior wall thickness.\textsuperscript{17,44} As in surgical myectomy,\textsuperscript{45} these findings must be interpreted as a result of the elimination of (or at least the reduction in) the pressure overload. Negative effects of the induced septal infarction, particularly left ventricular enlargement, have not been described. Preliminary studies have shown a reduction in reported risk factors for sudden cardiac death, such as exertional syncope, abnormal blood pressure response, and exercise-induced ischemia, after successful PTSMA.\textsuperscript{46}

**PERSPECTIVES**

Up to now, no randomized trials comparing surgical and percutaneous treatment with septal reduction in HOCM have been published.\textsuperscript{47} Non-randomized trials have shown significant reductions in left ventricular outflow tract (LVOT) obstruction and symptomatic improvement with both treatment options.\textsuperscript{48-50} Therefore, the benefits and drawbacks for each therapeutic method (Table 2) must be weighed when deciding on treatment for LVOT obstruction. This decision should take into consideration several clinical, morphological, and technical factors. Although there are some reports of successful combined simultaneous or diffuse percutaneous treatment of HOCM and coronary artery disease,\textsuperscript{25} it should be considered that surgery involves primarily the ability to deal with HOCM and coexistent heart diseases (such as coronary artery disease) or to perform valve replacement. In patients with HOCM and mitral regurgitation, pathological and morphologic findings in the mitral valve apparatus should determine the preferred treatment option. Overall, surgery and percutaneous septal ablation should be considered alternative approaches to HOCM. The final decision should be made on an individual basis for each patient in order to achieve optimal results. In addition to the points mentioned above, the individual experience of the center should be taken into consideration.

**CONCLUSION**

Nearly one decade after its introduction, percutaneous septal ablation is a promising treatment option for symptomatic patients with HOCM refractory to medical treatment. The morphological, hemodynamic, and clinical effects (Figure 2) have been well described. Intra-procedure echocardiographic monitoring results in optimal targeting of the area of the septum to be ablated, with concomitant reductions in peri-interventional complications and improved acute and medium-term hemodynamic results. However, possible complications and limited long-term effects mandate careful patient selection. In order to avoid overuse of the technique, we would emphasize the importance of restricting alcohol septal ablation to a few centers with extensive experien-

**TABLE 2. Advantages and potential drawbacks of percutaneous septal ablation and surgical myectomy**

<table>
<thead>
<tr>
<th>Percutaneous septal ablation (PTSMA)</th>
<th>Surgical myectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advantage</strong></td>
<td><strong>Potential drawbacks</strong></td>
</tr>
<tr>
<td>Avoidance of cardiopulmonary bypass with attendant risks (older patients with concomitant non-cardiac disease)</td>
<td>Risk of damage to the left coronary artery with emergency bypass surgery or left main/LAD stenting</td>
</tr>
<tr>
<td>Treatment of patients with isolated mid-cavitary or combined subaortic and mid-cavitary obstruction</td>
<td>Technical impossibility of reaching or identifying a target septal branch</td>
</tr>
<tr>
<td>Short hospital stay</td>
<td>Lower success in patients with mitral valve leaflet and papillary muscle abnormalities and with large septal thickness (younger patients)</td>
</tr>
<tr>
<td>Lower costs</td>
<td>LV deterioration after extended myectomy during long-term follow-up, possibly due to</td>
</tr>
<tr>
<td><strong>Potential drawbacks</strong></td>
<td>More invasive approach requiring extracorporal circulation</td>
</tr>
</tbody>
</table>

Advantage
Immediate and complete relief of resting and provoked obstruction and concomitant mitral regurgitation
Documented long-term results up to 30 years
Ability to treat coexistent cardiac diseases Short recovery time
Coronary artery disease, valve disease
Additional treatment of papillary muscle in extended myectomy

Potential drawbacks
Need for high individual level of surgical experience high surgical mortality at inexperienced centers
Low risk of postoperative aortic regurgitation
LV deterioration after extended myectomy during long-term follow-up, possibly due to

high incidence of left bundle branch block
ce in interventional and echocardiographic interventions and a solid knowledge of this uncommon disease.

REFERENCES


